Comparison of the ameliorative roles of crab chitosan nanoparticles and mesenchymal stem cells against cisplatin-triggered nephrotoxicity

Int J Biol Macromol. 2023 Jul 1;242(Pt 4):124985. doi: 10.1016/j.ijbiomac.2023.124985. Epub 2023 May 23.

Abstract

Aim: In the present investigation, we compared the effects of mesenchymal stem cells extracted from bone marrow (BMSCs) and crab chitosan nanoparticles (CCNPs) on renal fibrosis in cisplatin (CDDP)-induced kidney injury rats.

Material and methods: 90 male Sprague-Dawley (SD) rats were divided into two equal groups and alienated. Group I was set into three subgroups: the control subgroup, the CDDP-infected subgroup (acute kidney injury), and the CCNPs-treated subgroup. Group II was also divided into three subgroups: the control subgroup, the CDDP-infected subgroup (chronic kidney disease), and the BMSCs-treated subgroup. Through biochemical analysis and immunohistochemical research, the protective effects of CCNPs and BMSCs on renal function have been identified.

Results: CCNPs and BMSC treatment resulted in a substantial rise in GSH and albumin and a decrease in KIM-1, MDA, creatinine, urea, and caspase-3 when compared to the infected groups (p < 0.05).

Conclusion: According to the current research, chitosan nanoparticles and BMSCs may be able to reduce renal fibrosis in acute and chronic kidney diseases caused by CDDP administration, with more improvement of kidney damage resembling normal cells after CCNPs administration.

Keywords: Bone marrow mesenchymal stem cells; Cisplatin-triggered nephrotoxicity; Crab chitosan nanoparticles.

MeSH terms

  • Acute Kidney Injury* / chemically induced
  • Acute Kidney Injury* / pathology
  • Animals
  • Brachyura*
  • Chitosan* / pharmacology
  • Cisplatin / adverse effects
  • Fibrosis
  • Kidney
  • Male
  • Mesenchymal Stem Cells*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Cisplatin
  • Chitosan